Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer
| Status: | Completed |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | June 2006 |
| End Date: | March 2015 |
A Phase I/II Study of Autologous Dendritic Cells Pulsed With Apoptotic Tumor Cells (DC/PC3) Administered Subcutaneously to Prostate Cancer Patients.
The purpose of this study is to assess the safety and activity of DC/PC3, a dendritic cell
vaccine used as immunotherapy for prostate cancer. The vaccine is made with each
participants' own immune cells obtained through blood donation. Dendritic cells are known to
activate other immune cells such as T cells, that are able to mount an attack against cancer
cells. The dendritic cell vaccine will be administered as injections every 2 weeks over a
course of 2 months.
vaccine used as immunotherapy for prostate cancer. The vaccine is made with each
participants' own immune cells obtained through blood donation. Dendritic cells are known to
activate other immune cells such as T cells, that are able to mount an attack against cancer
cells. The dendritic cell vaccine will be administered as injections every 2 weeks over a
course of 2 months.
See Brief Summary.
Inclusion Criteria:
Prostate cancer
Rising prostate specific antigen (PSA, 3 values, each measured at least 2 weeks apart)
post initial therapy (ie, radiation, prostatectomy) human leukocyte antigen A2.1
(HLA-A2.1)
Exclusion Criteria:
central nervous system metastasis
History of autoimmune disease
We found this trial at
1
site
Click here to add this to my saved trials
